Insulin alone or with captopril: effects on signaling pathways (AKT and AMPK) and oxidative balance after ischemia-reperfusion in isolated hearts


Autoria(s): de Oliveira, Ubirajara Oliveira; Bello-Kein, Adriane; de Oliveira, Alvaro Reischak; Kuchaski, Luiz Carlos; Machado, Ubiratan Fabres; Irigoyen, Maria Claudia Costa; Schaan, Beatriz D'Agord
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

06/11/2013

06/11/2013

2012

Resumo

Insulin and the inhibition of the reninangiotensin system have independent benefits for ischemiareperfusion injury, but their combination has not been tested. Our aim was to evaluate the effects of insulin+captopril on insulin/angiotensin signaling pathways and cardiac function in the isolated heart subjected to ischemiareperfusion. Isolated hearts were perfused (Langendorff technique) with KrebsHenseleit (KH) buffer for 25 min. Global ischemia was induced (20 min), followed by reperfusion (30 min) with KH (group KH), KH+angiotensin-I (group A), KH+angiotensin-I+captopril (group AC), KH+insulin (group I), KH+insulin+angiotensin-I (group IA), or KH+insulin+angiotensin-I+captopril (group IAC). Group A had a 24% reduction in developed pressure and an increase in end-diastolic pressure vs. baseline, effects that were reverted in groups AC, IA, and IAC. The phosphorylation of protein kinase B (AKT) was higher in groups I and IA vs. groups KH and A. The phosphorylation of AMP-activated protein kinase (AMPK) was similar to 31% higher in groups I, IA, and IAC vs. groups KH, A, and AC. The tert-butyl hydroperoxide (tBOOH)-induced chemiluminescence was lower (similar to 2.2 times) in all groups vs. group KH and was similar to 35% lower in group IA vs. group A. Superoxide dismutase content was lower in groups A, AC, and IAC vs. group KH. Catalase activity was similar to 28% lower in all groups (except group IA) vs. group KH. During reperfusion of the ischemic heart, insulin activates the AKT and AMPK pathways and inhibits the deleterious effects of angiotensin-I perfusion on SOD expression and cardiac function. The addition of captopril does not potentiate these effects.

Capes

CAPES

CNPq

CNPq

Fapesp [2007/50554-1]

FAPESP

FAPERGS

Fapergs

Identificador

FUNDAMENTAL & CLINICAL PHARMACOLOGY, HOBOKEN, v. 26, n. 6, supl., Part 3, pp. 679-689, DEC, 2012

0767-3981

http://www.producao.usp.br/handle/BDPI/42541

10.1111/j.1472-8206.2011.00995.x

http://dx.doi.org/10.1111/j.1472-8206.2011.00995.x

Idioma(s)

eng

Publicador

WILEY-BLACKWELL

HOBOKEN

Relação

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Direitos

closedAccess

Copyright WILEY-BLACKWELL

Palavras-Chave #AMPK #ANGIOTENSIN-CONVERTING INHIBITOR #GLUT-4 #INSULIN-SIGNALING PATHWAY #REPERFUSION INJURY #PERFUSED RAT-HEART #ANGIOTENSIN-II #GLUT4 TRANSLOCATION #SUPEROXIDE-DISMUTASE #MYOCARDIAL-ISCHEMIA #HYPERTENSIVE-RATS #CARDIAC MYOCYTES #NAD(P)H OXIDASE #AT(2) RECEPTOR #MESSENGER-RNA #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion